Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 7Observational 3Expanded_access 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 13Gastrointestinal Stromal Tumors 7Ovarian Neoplasms 5Neoplasms 5Osteosarcoma 4Sarcoma, Ewing 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma 3Uterine Neoplasms 2Stomach Neoplasms 2Sarcoma, Synovial 2Rhabdoid Tumor 2Neuroectodermal Tumors, Primitive 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Hodgkin Disease 2Endometrial Neoplasms 2Desmoid Tumors 2Chondrosarcoma 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Rhabdomyosarcoma 1Retinoblastoma 1

Interventions

avapritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × GIST × Sarcoma × Clear all
NCT03862885 2020-07-27

Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST

Blueprint Medicines Corporation

Approved for marketing
Sarcoma

GIST

Data powered by HemOnc (CC BY 4.0) Colophon âš¡